Objectives Dental care during pregnancy is important. We examined whether promotion of oral health by medical providers during pregnancy and pregnant women's receipt of dental care improved between 2009 and 2012 in California. Methods We used population-based postpartum survey data collected during 2009 (n = 3105) and 2012 (n = 6810) to compare the prevalence of women's reports that, during pregnancy, (a) their medical providers discussed oral health and/or suggested they see a dentist, and (b) they received dental care. Results Between 2009 and 2012, the proportion of women reporting that their medical providers talked about oral health or referred them to a dentist increased significantly overall (from 36 to 42%, and 21-26%, respectively, p < 0.001). The proportion of women with a dental visit during pregnancy also increased, from 38% in 2009 to 42% in 2012 (p < 0.005). The improvements were largely among women of lower income and education levels, those covered by Medi-Cal, and Latinas. Women whose medical providers promoted oral health care were approximately two times more likely to report having had a dental visit during pregnancy, even after adjusting for several potential confounders. Conclusions for Practice Characteristics of women reporting that their medical providers promoted, and that they received, dental care during pregnancy in 2012 suggests that the increases in promotion and use of oral health care were largely concentrated among Medi-Cal recipients. Further improvement is needed for all populations of pregnant women. Both public and private providers need to incorporate promotion of and referral for dental care into routine prenatal care protocols.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10995-018-02714-z | DOI Listing |
J Prosthet Dent
January 2025
Professor, Department of Ophthalmology, Advanced Eye Center, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Bilateral anophthalmia, a clinical condition characterized by the absence of globe and ocular tissues from both the orbits, presents considerable challenges to a patient's daily routine and use of prostheses. The patient's inability to orientate custom ocular prostheses (COPs) 3-dimensionally is understandable, and they typically rely on caregivers to manage the prostheses and prevent inadvertent injury to the socket. This clinical report describes the successful integration of braille script into COPs as a solution to these challenges by improving prosthesis management, decreasing caregiver dependence, and encouraging independence.
View Article and Find Full Text PDFJ Stomatol Oral Maxillofac Surg
January 2025
Head of the Department of Oral and Maxillofacial Surgery, Lille University Hospital CHRU 59037 Lille Cedex, AIMOM, INSERM U1008, Université Nord de France, France. Electronic address:
Ann Allergy Asthma Immunol
January 2025
Allergy and Immunology Division, Department of Medicine, Montefiore Medical Center, Bronx, NY. Electronic address:
Pharmacol Res
January 2025
Department of Biochemistry, Imo State University, Owerri, Nigeria.
Phenolic acid-rich fraction from Anisopus mannii (PhAM) contains abundance of ferulic acid, gallic acid, protocatechuic acid, and syringic acid. Among other glycolytic enzymes, in vitro, PhAM counteracted the binding of sodium orthovanadate to phosphofructokinase 1 (PFK-1), improving its activities. In a rat model of diet-induced diabetes, PhAM monotherapy reduced HbA1c by an average of 0.
View Article and Find Full Text PDFLancet Diabetes Endocrinol
January 2025
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Electronic address:
Background: Data on the effect of mineralocorticoid receptor antagonist therapy on HbA levels and new-onset diabetes are conflicting. We aimed to examine the effect of oral finerenone, compared with placebo, on incident diabetes in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF) trial.
Methods: In this randomised, double-blind, placebo-controlled trial, 6001 participants with heart failure with New York Heart Association functional class II-IV, left ventricular ejection fraction 40% or higher, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomly assigned to finerenone or placebo, administered orally.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!